Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2012
05/31/2012US20120136338 Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer
05/31/2012US20120136157 Aryl ureas as kinase inhibitors
05/31/2012US20120136153 Camptothecin analogs and methods of preparation thereof
05/31/2012US20120136063 Fty720-derived anticancer agents
05/31/2012US20120136061 Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
05/31/2012US20120136057 Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
05/31/2012US20120136055 Semi-solid compositions and pharmaceutical products
05/31/2012US20120136040 Hybrid interfering rna
05/31/2012US20120136034 Fatty acids as anti-inflammatory agents
05/31/2012US20120136033 Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof
05/31/2012US20120136031 P38map kinase inhibitor
05/31/2012US20120136030 Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
05/31/2012US20120136029 Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
05/31/2012US20120136026 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120136004 New combination therapy in treatment of cancer and fibrotic diseases
05/31/2012US20120136002 Protease inhibitors
05/31/2012US20120136000 Tri-cyclic pyrazolopyridine kinase inhibitors
05/31/2012US20120135994 Inhibitors of human phosphatidylinositol 3-kinase delta
05/31/2012US20120135992 Cyclic triazo sodium channel blockers
05/31/2012US20120135990 Iap inhibitors
05/31/2012US20120135989 Azaindole derivative
05/31/2012US20120135988 Purine pi3k inhibitor compounds and methods of use
05/31/2012US20120135986 Bicyclic Heteroaryl Compounds
05/31/2012US20120135985 Substituted piperidines
05/31/2012US20120135983 DNA Damage Repair Inhibitors for the Treatment of Cancer
05/31/2012US20120135972 Phthalocyanine derivative consisting of a mixture of 4 isomers
05/31/2012US20120135959 Metalloprotein inhibitors containing nitrogen based ligands
05/31/2012US20120135952 Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
05/31/2012US20120135950 Antiviral treatment of lymphoma and cancer
05/31/2012US20120135944 Inhibitors of bruton's tyrosine kinase
05/31/2012US20120135942 Beta-hairpin peptidomimetics
05/31/2012US20120135941 Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
05/31/2012US20120135938 Polypeptides that Bind TRAIL-R1 and TRAIL-R2
05/31/2012US20120135930 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
05/31/2012US20120135926 Peptides for inhibiting igf-1
05/31/2012US20120135921 Tripetide boronic acid or boronic ester, preparative method and use thereof
05/31/2012US20120135916 Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
05/31/2012US20120135914 Etoposide and doxorubicin conjugates for drug delivery
05/31/2012US20120135501 Recombinant poxvirus expressing homologous genes inserted
05/31/2012US20120135066 Regulators of the hedgehog pathway, compositions and uses related thereto
05/31/2012US20120135054 Poly (Ester Ether Amide)s and Uses Thereof
05/31/2012US20120135042 Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias
05/31/2012US20120135041 Immunosuppressor based on the blockage of tcr-nck interaction
05/31/2012US20120135034 Non-Integrating Retroviral Vector Vaccines
05/31/2012US20120135033 Multiple delivery system for heterologous antigens
05/31/2012US20120135031 Method of enhancing an immune response
05/31/2012US20120135022 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
05/31/2012US20120135021 Cell penetrating peptides and its use fused to biomolecules with therapeutic action
05/31/2012US20120135020 Ttk peptides and vaccines including the same
05/31/2012US20120135018 Erg monoclonal antibodies
05/31/2012US20120135016 Induction of neurogenesis and stem cell therapy in combination with copolymer 1
05/31/2012US20120135011 Method for in vivo expansion of T regulatory cells
05/31/2012US20120135008 Methods and compositions for targeting polyubiquitin
05/31/2012US20120135004 Antibodies to matrix metalloproteinase 9
05/31/2012US20120135002 Compounds and Methods for the Treatment of Cancer
05/31/2012US20120135001 Combination of anti-ctla4 antibody with dasatinib for the treatment of proliferative diseases
05/31/2012US20120134997 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
05/31/2012US20120134996 Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products
05/31/2012US20120134995 Method for predicting the therapeutic responseiveness of a patient to a medical treatment with an egfr inhibitor
05/31/2012US20120134994 Monoclonal antibodies to fibroblast growth factor receptor 2
05/31/2012US20120134993 Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
05/31/2012US20120134990 Combination therapy with type i and type ii anti-cd20 antibodies
05/31/2012US20120134989 Antibody formulations
05/31/2012US20120134987 Kinase inhibitors and methods of their use
05/31/2012US20120134986 Methods of Prognosis for Non-Hodgkin Lymphoma
05/31/2012US20120134975 Biological targeting compositions and methods of using the same
05/31/2012US20120134970 Viral Vectors Encoding Multiple Highly Homologus Non-Viral Polypeptides And The Use Of Same
05/31/2012US20120134966 Embryonic stem cell specific micrornas promote induced pluripotency
05/31/2012US20120134964 Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus
05/31/2012US20120134963 Compositions and methods for enhancing virus efficacy
05/31/2012US20120134961 Interferon-alpha (IFN-alpha) Fused Protein Having IFN-alpha and Cytoplasmic Transduction Peptide (CTP)
05/31/2012US20120134960 Glycosylated human alpha interferon muteins, method for obtaining them and use
05/31/2012US20120134959 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
05/31/2012US20120134956 Colloidal metal compositions and methods
05/31/2012US20120134955 Pyrimidopyrimidoindazole derivative
05/31/2012US20120134954 Defensin-antigen fusion proteins
05/31/2012US20120134918 Gum arabic coated 198gold radioactive nanoparticles for cancer therapy
05/31/2012DE102005023301B4 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat A pharmaceutical composition comprising progestins and / or estrogens and 5-methyl- (6S) -tetrahydrofolate
05/31/2012CA2856812A1 Carbonic anhydrase inhibitors with antimetastatic activity
05/31/2012CA2849207A1 Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compounds
05/31/2012CA2818898A1 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and mmanufacture
05/31/2012CA2818871A1 Integrin-linked kinase inhibitors
05/31/2012CA2818813A1 Anti-il-6 antibodies for the treatment of oral mucositis
05/31/2012CA2818701A1 Modulating oncolytic vsv and upregulating rae1 and nup98 with statins
05/31/2012CA2818694A1 177lutetium-labeled bombesin analogs for radiotherapy
05/31/2012CA2818684A1 Nk cell modulating treatments and methods for treatment of hematological malignancies
05/31/2012CA2818647A1 Selective removal of cells having accumulated agents
05/31/2012CA2817629A1 Salts and crystalline forms of an apoptosis-inducing agent
05/31/2012CA2815029A1 Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
05/30/2012EP2458005A1 Fgf21 cis-element binding substance
05/30/2012EP2457928A2 Monoclonal human tumor-specific antibody
05/30/2012EP2457921A2 Aureolic acid derivatives, the method for preparation thereof and the uses thereof
05/30/2012EP2457913A2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith
05/30/2012EP2457907A1 Flavagline derivatives as neuroprotective agents
05/30/2012EP2457896A1 Tripeptides as caspase modulators
05/30/2012EP2457895A1 Tetrapeptide analogs
05/30/2012EP2457588A1 Microsphere comprising a lanthanide metal complex
05/30/2012EP2457572A1 Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
05/30/2012EP2457096A2 Phenotyping tumor-infiltrating leukocytes
05/30/2012EP2456790A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 2211